INOVIO to Participate in Upcoming Scientific and Investor Conferences

INOVIO (NASDAQ: INO) reported Q2 2026 results and said the FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is progressing toward a PDUFA target date of Oct. 30, 2026. Cash and investments were $36.7M at June 30, 2026. Net loss was $6.0M. ApolloBio reported positive Phase 3 topline results for VGX-3100 in China.

INOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ino-63026x8kex991.htm EX-99.1 Document Exhibit 99.1 INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights • U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Resp

Inovio Pharmaceuticals (NASDAQ:INO) shares fell 30.8% in Thursday premarket after the company priced a $20 million underwritten public offering at $0.95 per share. It will sell 21,052,632 shares plus warrants for up to 42,105,264 shares, with warrants priced at a $1.10 exercise price. Piper Sandler is sole manager.

INOVIO Pharmaceuticals (Nasdaq: INO) priced an underwritten public offering of 21,052,632 shares plus warrants to buy up to 42,105,264 shares, or pre-funded warrants, at a combined price of $0.95 per share and $1.10 warrant exercise price. Gross proceeds are about $20.0 million, excluding option/warrant exercise. Closing expected around July 31, 2026.

INOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001055726 0001055726 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 20

Inovio Pharmaceuticals said the FDA completed a standard mid-cycle review of its BLA for INO-3107 for recurrent respiratory papillomatosis, with “no new significant issues,” and scheduled the late-cycle review for Q3. The company expects an informal meeting on an Accelerated Approval eligibility question. Inovio reported $37.7M cash at Q1 2026, reduced 2025 operating spend 23%, and expects runway into Q1 2027.